[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"right-hemicolectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:right-hemicolectomy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100603165","leakage-rate-of-ileo-colic-sutured-anastomosis-after-right-hemicolectomy-100603165",false,"NCT07132970","Leakage Rate of Ileo-COlic Sutured Anastomosis After Right Hemicolectomy","Assessment of the Leakage Rate of Ileo-colic Sutured Anastomoses Using a Polydioxanone Based Suture Material After Laparoscopic or Open Right Hemicolectomy to Treat Malignancy","LICOSARH","Inclusion Criteria:\n\n* Patients undergoing a primary, elective either open or laparoscopic right hemicolectomy or right extended hemicolectomy due to malignancy with the creation of an intracorporeal or extracorporeal ileo-colic anastomosis.\n* Either complete hand-sewn anastomosis or partial sutured anastomosis (e.g. combination of stapling and suturing)\n* Open or laparoscopic as well as conversion from open to laparoscopic surgery\n* Absence of peritoneal carcinomatosis\n* Absence of vascular, nervous or bone infiltration\n* Age ≥ 18 years\n* Written data protection declaration (Written Informed consent)\n\nExclusion Criteria:\n\n* Left hemicolectomy or left extended hemicolectomy or sigma resection\n* Inflammatory bowel disease (e.g. Crohn´s disease)\n* Emergency surgery\n* Previous abdominal surgery with bowel resection\n* Re-operation of an anastomosis (anastomosis revision surgery)\n* Need for stoma creation\n* Non-compliant patients\n* Participation in an interventional randomized controlled study (RCT)","ALL","18 Years",{"count":20,"type":21},249,"ESTIMATED","OBSERVATIONAL","The primary aim of the study is to show that the ileo-colic anastomosis leakage rate until the first 30 days after surgery using MonoPlus® suture material for anastomosis construction after right hemicolectomy is not inferior to the anastomosis leakage rate published in the literature for totally handsewn or stapled-handsewn ileo-colic anastomosis.",[25,26,27],"Anastomotic Leak","Colon Cancer","Right Hemicolectomy","RECRUITING","2026-06-08",{"date":31,"type":32},"2026-06-09","ACTUAL",{"date":34,"type":32},"2026-01-26",{"date":36,"type":21},"2028-03",{"name":38,"class":39},"Aesculap AG","INDUSTRY",4,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100603618","the-intraoperative-technical-errors-of-robotic-vs-laparoscopic-radical-right-hemiclectomy-100603618","NCT07138859","The Intraoperative Technical Errors of Robotic vs. Laparoscopic Radical Right Hemiclectomy","Prospective, Multiceter, Randomized, Controlled Study on the Intraoperative Technical Errors of Robotic vs. Laparoscopic Radical Right Hemiclectomy (Superiority Design，ROBOGEON® 2501study)","Inclusion Criteria:\n\n1. 18 years old\\\u003Cage\\\u003C80 years old, regardless of gender;\n2. The primary lesion of the colon was diagnosed as colon adenocarcinoma (well differentiated adenocarcinoma, moderately differentiated adenocarcinoma, poorly differentiated adenocarcinoma, mucinous adenocarcinoma) through endoscopic biopsy tissue pathology;\n3. The preoperative clinical staging was cStage I-III (cT1-4a, N0\u002F+, M0) (according to UICC\u002FAJCC-8thTNM tumor staging);\n4. The primary lesions of the colon are located in the cecum, ascending colon, hepatic flexure of the colon, and right half of the transverse colon. It is expected that right-sided colectomy and D3 lymph node dissection can achieve R0 surgical results (excluding multiple primary cancers);\n5. Preoperative examination showed no distant metastasis, and the tumor did not directly invade adjacent organs;\n6. Preoperative ECOG physical status score ≤ 2;\n7. Preoperative ASA scores I-III;\n8. Patient informed consent.\n\nExclusion Criteria:\n\n1. History of colon surgery (excluding ESD\u002FEMR for colon cancer);\n2. History of major abdominal surgery (excluding laparoscopic cholecystectomy and appendectomy);\n3. Preoperative body temperature ≥ 38 ℃ or complicated with infectious diseases requiring systematic treatment;\n4. Pregnant or lactating women;\n5. Suffering from severe mental illness;\n6. Multiple primary cancers;\n7. History of other malignant diseases within 5 years;\n8. Any neoadjuvant therapy such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. has been implemented;\n9. History of unstable angina or myocardial infarction within 6 months;\n10. Heart, lung, liver, kidney dysfunction or history of cerebral infarction;\n11. Simultaneous surgical treatment is required for other diseases;\n12. Colorectal cancer complications (bleeding, perforation, obstruction) require emergency surgery.","80 Years",{"count":50,"type":21},368,"INTERVENTIONAL",[53],"NA","Experimental design: This study is a multicenter, prospective, randomized, controlled phase III clinical trial that identifies, classifies, defines, and quantitatively analyzes technical errors between robotic and laparoscopic radical right hemicolectomy (D3 lymph node dissection), identifies surgical risk areas, compares intraoperative performance, and patient short-term and long-term clinical outcomes.\n\nThis experimental design was based on a 1:1 effective target case ratio between the experimental group and the control group for enrollment. The experimental group underwent robotic radical right hemicolectomy (D3 lymph node dissection), while the control group underwent laparoscopic radical right hemicolectomy (D3 lymph node dissection). The unedited surgical videos of patients were analyzed, and relevant indicators and adverse events were recorded. Patients were followed up in the outpatient department after discharge until 3 years after surgery or until death or recurrence.\n\nSample size calculation: In this study, the calculation of sample size was based on pre experiments and hypotheses, and a goodness test was conducted by selecting the means of two independent samples. Referring to the results of the pilot study, based on a 1:1 random (random number table method) ratio, assuming a significance level of unilateral α=0.025, a test power of 1- β=80%, and a superiority margin of 20% in reducing the number of errors, and considering the maximum dropout rate of 0.1 in this clinical study, the total sample size for this study was determined to be 368 patients (184 in the RRC group and 184 in the LRC group).\n\nPrimary endpoint: incidence of technical errors during right hemicolectomy. Secondary endpoint: incidence of intraoperative complications; The incidence of complications within 30 days after surgery; Total surgical time, robot\u002Flaparoscope time; Estimate the amount of blood loss; Conversion to open surgery rate; Postoperative hospitalization time; Total number of lymph nodes cleared and positive rate of lymph nodes; Early postoperative recovery process (time of first defecation and defecation); 30 day readmission rate and unplanned reoperation rate after surgery; Postoperative nutritional status, inflammation, and immune response; 3-year disease-free survival rate DFS; 3-year overall survival rate (OS).\n\nInclusion criteria: 1) 18 years old\\\u003Cage\\\u003C80 years old, regardless of gender; 2) The primary lesion of the colon was diagnosed as colon adenocarcinoma (well differentiated adenocarcinoma, moderately differentiated adenocarcinoma, poorly differentiated adenocarcinoma, mucinous adenocarcinoma) through endoscopic biopsy tissue pathology; 3) The preoperative clinical staging was cStage I-III (cT1-4a, N0\u002F+, M0) (according to UICC\u002FAJCC-8thTNM tumor staging); 4) The primary lesions of the colon are located in the cecum, ascending colon, hepatic flexure of the colon, and right half of the transverse colon. It is expected that right-sided colectomy and D3 lymph node dissection can achieve R0 surgical results (excluding multiple primary cancers); 5) Preoperative examination showed no distant metastasis, and the tumor did not directly invade adjacent organs; 6) Preoperative ECOG physical status score ≤ 2; 7) Preoperative ASA scores I-III; 8) Patient informed consent.\n\nExclusion criteria: 1) History of colon surgery (excluding ESD\u002FEMR for colon cancer); 2) History of major abdominal surgery (excluding laparoscopic cholecystectomy and appendectomy); 3) Preoperative body temperature ≥ 38 ℃ or complicated with infectious diseases requiring systematic treatment; 4) Pregnant or lactating women; 5) Suffering from severe mental illness; 6) Multiple primary cancers; 7) History of other malignant diseases within 5 years; 8) Any neoadjuvant therapy such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. has been implemented; 9) History of unstable angina or myocardial infarction within 6 months; 10) Heart, lung, liver, kidney dysfunction or history of cerebral infarction; 11) Simultaneous surgical treatment is required for other diseases; 12) Colorectal cancer complications (bleeding, perforation, obstruction) require emergency surgery.",[56,27],"Colorectal Carcinoma (CRC)",[56,58,59,60,61,62,63],"right hemicolectomy","Robotic surgery","Errors","Intraoperative bleeding","Dangerous areas","Clinical outcome","NOT_YET_RECRUITING","2025-08-17",{"date":67,"type":32},"2025-08-24",{"date":69,"type":21},"2025-08",{"date":71,"type":21},"2030-12",{"name":73,"class":74},"The Affiliated Hospital of Qingdao University","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":51,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100597588","phase-2-fluorescence-lymph-node-mapping-for-colon-cancer-surgery-100597588","NCT07060443","Fluorescence Lymph Node Mapping for Colon Cancer Surgery","Clinico-oncological Safety and Efficacy of Real-time Fluorescence Lymph Node Mapping (FLNM) in Laparoscopic and Robotic Right Hemicolectomy for Patients With Locally Advanced Right-sided Colon Cancer; Multicenter Phase II Open Labelled Randomized Controlled Trial","CONSTELLARE","Inclusion Criteria:\n\n1. Patients who over 19 years old, Under 85 years old\n2. Patient with locally advanced right colon cancer requiring D3 lymphadenectomy\n3. Colon cancer patients diagnosed with clinical stage cT3-4 N0 or cTany N1-2 before surgery\n4. Patient with right-sided colon cancer located in the cecum, ascending colon, flexure colon, and proximal transverse colon.\n5. Patients with American Society of Anesthesiology (ASA) I-III\n6. Patients who agreed to the research purpose and voluntarily gave informed consent\n\nExclusion Criteria:\n\n1. Patients with a history of allergy or side effects to sodium iodine\n2. Patients with colon cancer who have distant or peritoneal metastases\n3. Patients requiring emergency surgery due to colon obstruction or colon perforation\n4. Patients with inflammatory bowel disease not controlled by drug treatment\n5. Patients with concurrent cancer in other areas other than colon cancer\n6. Patients with a history of hereditary disease or coagulopathy at risk of bleeding\n7. Women who are pregnant or may be pregnant and lactating women\n8. Patients with chronic renal failure (e-GFR \\\u003C 15) or patients receiving dialysis at the time of screening\n9. Patients diagnosed with liver failure or with decreased consciousness due to hepatic encephalopathy\n10. Patients judged to have difficulty in smooth lymph perfusion due to heart disease (acute myocardial infarction, acute and chronic heart failure) within the past 6 months\n11. Patients unable to undergo general anesthesia\n12. Patients with American Society of Anesthesiology (ASA) IV or V\n13. Patients who do not wish to participate in this study\n14. Patients who are judged by the researcher to be unsuitable for participation in this clinical trial (Example: People with a life expectancy of less than 6 months, people expected to have low compliance with clinical trials, etc.)","19 Years","85 Years",{"count":87,"type":21},186,[89],"PHASE2","Fluorescence-guided surgery using indocyanine green can visualize the complex and diverse lymph node drainage structures for each patient and help determine the extent of dissection of the D3 lymph node tailored to the patient. However, since fluorescence lymph node mapping (FLNM) is still being conducted only at some institutions for research purposes and is limited to reporting the results of small-scale studies of patients, a large-scale multi-center study was conducted to verify the clinical-oncological effects of FLNM. Research is needed.\n\nTherefore, this study used real-time fluorescence lymph node mapping (FLNM) to determine the extent of D3 lymph node dissection when performing right hemicolectomy and D3 lymph node dissection in patients with locally advanced right-sided colon cancer and to safely remove extensive lymph nodes. We aim to evaluate whether the dissection procedure is safe and beneficial in terms of clinical oncology.",[27],"2025-07-01",{"date":94,"type":32},"2025-07-11",{"date":96,"type":21},"2025-07-23",{"date":98,"type":21},"2030-12-31",{"name":100,"class":74},"Pusan National University Yangsan Hospital",13]